MAM-E17 rat model impairments on a novel continuous performance task: effects of potential cognitive enhancing drugs.

ABSTRACT:

Rationale

Impairments in attention and inhibitory control are endophenotypic markers of neuropsychiatric disorders such as schizophrenia and represent key targets for therapeutic management. Robust preclinical models and assays sensitive to clinically relevant treatments are crucial for improving cognitive enhancement strategies.

Objectives

We assessed a rodent model with neural and behavioral features relevant to schizophrenia (gestational day 17 methylazoxymethanol acetate treatment (MAM-E17)) on a novel test of attention and executive function, and examined the impact of putative nootropic drugs.

Methods

MAM-E17 and sham control rats were trained on a novel touchscreen-based rodent continuous performance test (rCPT) designed to closely mimic the human CPT paradigm.

SUBMITTER: Mar AC 

PROVIDER: S-EPMC5591806 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature